110 related articles for article (PubMed ID: 28446401)
1. [Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer].
Liu S; Liu YY; Li R
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):488-493. PubMed ID: 28446401
[TBL] [Abstract][Full Text] [Related]
2. [Coexpression of MAP2K4 and vimentin proteins in human endometrial carcinoma and its clinicopathological significance].
Liu CH; Jiang QP; Lin D; Chen W; Xiao YY; Lin L; Deng YR; Jiang HP; Guo SQ
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Feb; 37(2):157-164. PubMed ID: 28219857
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of ILK1 in breast cancer associates with poor prognosis.
Yang HJ; Zheng YB; Ji T; Ding XF; Zhu C; Yu XF; Ling ZQ
Tumour Biol; 2013 Dec; 34(6):3933-8. PubMed ID: 23832543
[TBL] [Abstract][Full Text] [Related]
4. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
5. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.
El-Gendi SM; Mostafa MF
Pathol Oncol Res; 2016 Jul; 22(3):461-70. PubMed ID: 26597806
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
7. [High expression of cyclin D1 is correlated with the expression of estrogen receptor and good prognosis in breast cancer].
Yang C; Nan K; Zhang Y; Chen Y; Qin S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jan; 32(1):84-7. PubMed ID: 26728382
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
9. Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER Status.
Lidfeldt J; Bendahl PO; Forsare C; Malmström P; Fernö M; Belting M
PLoS One; 2015; 10(8):e0134932. PubMed ID: 26244666
[TBL] [Abstract][Full Text] [Related]
10.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic values of grading system for lymph vessel tumor emboli in patients with invasive breast carcinomas of no special type].
Yue M; Li F; Deng HY; Zhang LL; Liu YP
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):754-758. PubMed ID: 29061019
[No Abstract] [Full Text] [Related]
12. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
13. ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer.
Ma B; Ma Q; Jin C; Wang X; Zhang G; Zhang H; Seeger H; Mueck AO
Int J Clin Exp Pathol; 2015; 8(10):13279-83. PubMed ID: 26722530
[TBL] [Abstract][Full Text] [Related]
14. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
[TBL] [Abstract][Full Text] [Related]
15. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
16. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis.
Tong ZJ; Shi NY; Zhang ZJ; Yuan XD; Hong XM
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28667103
[TBL] [Abstract][Full Text] [Related]
18. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
20. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.
Chan HJ; Li H; Liu Z; Yuan YC; Mortimer J; Chen S
Oncotarget; 2015 Sep; 6(28):25815-27. PubMed ID: 26158350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
